Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphoma

References

• Zucca E, Bertoni F, Yahalom J, et al. Extranodal marginal zone B-cell lymphoma of mucosaassociated lymphoid tissue (MALT lymphoma). In: Armitage JO, Coiffier B, Dalla-Favera R, Harris NL, Mauch PM, editors. Non-Hodgkin lymphomas. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2010. p. 232–253.
   Google Scholar
• Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61:507–513.
   PubMed Web of Science ®Google Scholar
• Amiot A, Lévy M, Copie-Bergman C, et al. Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study. Aliment Pharmacol Ther. 2014;39:619–628.
   PubMed Web of Science ®Google Scholar
• Zucca E, Copie-Bergman C, Ricardi U, et al. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi144–vi148.
   PubMed Web of Science ®Google Scholar
• Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013;31:565–572.
   PubMed Web of Science ®Google Scholar
• Oka K, Nagayama R, Yonekawa N, et al. Concurrent gastric MALT and Hodgkin lymphoma: a case report. Int J Surg Pathol. 2012;20:201–204.
   PubMed Web of Science ®Google Scholar
• Capelle LG, de Vries AC, Looman CWN, et al. Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer. 2008;44:2470–2476.
   PubMed Web of Science ®Google Scholar
• Terada T. One patient with double lymphomas: simultaneous gastric MALT lymphoma and ileal diffuse large B-cell lymphoma. Int J Clin Exp Pathol. 2012;5:260–263.
   PubMed Web of Science ®Google Scholar
• Luppi M, Longo G, Ferrari MG, et al. Additional neoplasms and HCV infection in low-grade lymphoma of MALT type. Br J Haematol. 1996;94:373–375.
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Locher C, Levy M, et al. Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma? Ann Oncol. 2005;16:1232–1236.
   PubMed Web of Science ®Google Scholar
• Abraham C, Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology. 2011;140:1729–1737.
   PubMed Web of Science ®Google Scholar
• Tajika M, Matsuo K, Ito H, et al. Risk of second malignancies in patients with gastric marginal zone lymphomas of mucosa associate lymphoid tissue (MALT). J Gastroenterol. 2014;49:843–852.
   PubMed Web of Science ®Google Scholar
• Zucca E, Pinotti G, Roggero E, et al. High incidence of other neoplasms in patients with low-grade gastric MALT lymphoma. Ann Oncol. 1995;6:726–728.
   PubMed Web of Science ®Google Scholar
• Hamaloglu E, Topaloglu S, Ozdemir A, et al. Synchronous and metachronous occurrence of gastric adenocarcinoma and gastric lymphoma: A review of the literature. World J Gastroenterol. 2006;12:3564–3574.
   PubMed Web of Science ®Google Scholar
• Montalbàn C, Castrillo JM, López-Abente G, et al. Other cancers in patients with gastric MALT lymphoma. Leuk Lymphoma. 1999;33:161–168.
   PubMed Web of Science ®Google Scholar
• Au WY, Gascoyne RD, Le N, et al. Incidence of second neoplasms in patients with MALT lymphoma: no increase in risk above the background population. Ann Oncol. 1999;10:317–321.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;372:1441–1452.
   PubMed Web of Science ®Google Scholar
• Sherston SN, Carroll RP, Harden PN, et al. Predictors of cancer risk in the long-term solid-organ transplant recipient. Transplantation. 2014;97:605–611.
   PubMed Web of Science ®Google Scholar
• Isaacson PG, Chott A, Nakamura S, et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008. p. 214–217.
   Google Scholar
• Tankovic J, Lamarque D, Lascols C, et al. Clarithromycin resistance of Helicobacter pylori has a major impact on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. Pathol Biol (Paris). 2001;49:528–533.
   PubMed Web of Science ®Google Scholar
• Lévy M, Copie-Bergman C, Amiot A, et al. Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study. Leuk Lymphoma. 2013;54:940–944.
   PubMed Web of Science ®Google Scholar
• Ruskoné-Fourmestraux A, Fischbach W, Aleman BMP, et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut. 2011;60:747–758.
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Wotherspoon AC, Capella C, et al. Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. Br J Haematol. 2013;160:47–52.
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Gaulard P, Lavergne-Slove A, et al. Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma. Gut. 2003;52:1656.
   PubMed Web of Science ®Google Scholar
• Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362:1417–1429.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Calvet X. Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphoma. Aliment Pharmacol Ther. 2011;34:1047–1062.
   PubMed Web of Science ®Google Scholar
• Wündisch T, Dieckhoff P, Greene B, et al. Second cancers and residual disease in patients treated for gastric mucosa-associated lymphoid tissue lymphoma by Helicobacter pylori eradication and followed for 10 years. Gastroenterology. 2012;143:936–942. 14.
   PubMed Web of Science ®Google Scholar
• Lévy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol. 2005;23:5061–5066.
   PubMed Web of Science ®Google Scholar
• Sagaert X, Van Cutsem E, De Hertogh G, et al. Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development. Nat Rev Gastroenterol Hepatol. 2010;7:336–346.
   PubMed Web of Science ®Google Scholar
• Lamarque D, Levy M, Chaumette M-T, et al. Frequent and rapid progression of atrophy and intestinal metaplasia in gastric mucosa of patients with MALT lymphoma. Am J Gastroenterol. 2006;101:1886–1893.
   PubMed Web of Science ®Google Scholar